{"id":"W2142226415","doi":"10.1016/s1470-2045(15)70064-1","title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":285,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Fudan University; Natural Science Foundation of Shanghai; Eli Lilly and Company","keywords":"Gemcitabine; Medicine; Internal medicine; Regimen; Metastatic breast cancer; Oncology; Breast cancer; Clinical endpoint; Triple-negative breast cancer; Chemotherapy; Cisplatin; Paclitaxel; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001800606,0.0005882193,0.002434988,0.0001461258,0.0002965722,0.0000614093,0.0006509187,0.0002235106,0.001248354],"category_scores_gemma":[0.0008203833,0.0003809833,0.0002317298,0.0004474804,0.0003393879,0.0002175304,0.0001926221,0.0005145154,0.0001155399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001862108,"about_ca_system_score_gemma":0.002480096,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001923506,"about_ca_topic_score_gemma":0.00241164,"domain_scores_codex":[0.9962587,0.0007251907,0.0008901448,0.0007166208,0.0003915396,0.001017764],"domain_scores_gemma":[0.9945408,0.00320089,0.0006327415,0.0006405961,0.0005053036,0.0004796694],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9090307,0.004357888,0.0000203957,0.00007259145,0.002321832,0.0001344575,0.002594487,0.0001061144,0.0004739315,0.000220169,0.05906511,0.02160228],"study_design_scores_gemma":[0.8819357,0.02629163,0.00004038019,0.00005169508,0.002097527,0.0001189111,0.0006126682,0.003937567,0.0003712756,0.0006003404,0.08357895,0.0003633707],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.86695,0.005018692,0.0003033056,0.08364437,0.00714631,0.02800345,0.002436406,0.0002164707,0.00628097],"genre_scores_gemma":[0.9301834,0.007571583,0.005067242,0.01099088,0.01056574,0.01940379,0.00116805,0.0002595826,0.01478975],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07265349,"threshold_uncertainty_score":0.9998642,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2756851049856489,"score_gpt":0.4983969678085888,"score_spread":0.2227118628229399,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}